Anti-Vascular Endothelial Growth Factor Therapeutics Market to Gain US$ 1.1 Bn in Opportunity by 2032: Persistence Market Research

✅ Market Overview: Growth Potential Amid Aging Populations and Rising Ophthalmic Conditions

The Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market has demonstrated steady, albeit modest, growth over recent years. In 2021, global sales stood at US$ 11.9 billion, and this figure reached US$ 12 billion by 2022. Market projections indicate an increase to approximately US$ 13.1 billion by 2032, with a compound annual growth rate (CAGR) of 0.9% for the forecast period from 2022 to 2032. While historical CAGR from 2015 to 2021 remained at 0.7%, market demand is expected to slightly outpace that in the coming decade due to the global rise in chronic eye conditions and certain cancers.

Key growth drivers include the increasing prevalence of ophthalmic diseases like diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion. These conditions are particularly common among the aging population. This demographic shift, combined with enhanced diagnostic capabilities and healthcare access in developing nations, has provided momentum for the market. Among product types, Eylea has emerged as the top revenue-generating drug, thanks to its efficacy and convenient prefilled syringe formulation. North America leads globally, contributing over 40% of total revenues in 2021, propelled by robust healthcare infrastructure, a high prevalence of age-related disorders, and ongoing research and development in biologics and anti-angiogenesis therapies.

✅Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/33243

✅ Key Highlights from the Report

➤ The global Anti-VEGF Therapeutics Market is projected to grow from US$ 12 Bn in 2022 to US$ 13.1 Bn by 2032.
➤ North America accounted for more than 40% of global revenue in 2021.
➤ Eylea remains the top-selling product due to its strong clinical outcomes and ease of administration.
➤ Age-related macular degeneration continues to drive substantial demand in the ophthalmology segment.
➤ The market is seeing steady expansion in Japan, with a CAGR of 1.2% projected through 2032.
➤ The United States is expected to reach a valuation of US$ 4.6 Bn by 2032, showcasing its leadership in clinical innovation.

✅ Market Segmentation: Products and Indications Leading the Way

The Anti-VEGF Therapeutics Market is segmented primarily by product type and disease indication, each representing significant variations in adoption and growth. Under the product category, Eylea, Lucentis, and Beovu stand as the three dominant treatments. Eylea leads the market due to superior drug delivery mechanisms and clinical effectiveness. It has set a benchmark for intravitreal injections that deliver high efficacy with fewer side effects. Beovu and Lucentis also contribute significantly but have faced intermittent scrutiny over adverse events.

In terms of disease indication, the market is heavily dominated by treatments for Age-related Macular Degeneration (AMD), followed by Diabetic Retinopathy, Macular Edema, and Retinal Vein Occlusion. AMD alone accounts for a substantial share, particularly in populations over the age of 65. The increasing prevalence of diabetes has also made Diabetic Retinopathy and Diabetic Macular Edema key focus areas. With nearly 30% of patients suffering vision impairment after 20 years of diabetes, anti-VEGF therapies are becoming frontline treatments to slow disease progression and preserve vision.

✅ Regional Insights: Trends in Leading and Emerging Markets

North America, particularly the U.S., is the dominant force in the Anti-VEGF Therapeutics Market. It benefits from a combination of a large geriatric population, advanced diagnostic infrastructure, and strong regulatory support. The U.S. market alone is forecasted to grow to US$ 4.6 billion by 2032. Favorable reimbursement frameworks and a high prevalence of lifestyle-related diseases like diabetes and cardiovascular conditions further support the market's expansion in the region.

In Europe and Asia-Pacific, the market is witnessing diversified growth. The U.K. is anticipated to reach US$ 527 million by 2032, while Japan is expected to hit US$ 455 million, growing at a robust CAGR of 1.2%. Japan's aging population is a significant driver. Meanwhile, emerging economies in Asia and Latin America are catching up due to increased healthcare investments and awareness programs targeting diabetic and age-related ocular conditions.

✅ Market Dynamics

Market Drivers

The primary driver of the Anti-VEGF Therapeutics Market is the increasing incidence of ophthalmic and oncological disorders, particularly among the aging population. The United Nations reports that individuals aged 60 and over will double by 2050, reaching more than 2 billion. This demographic is at high risk of AMD, DME, and other retinal diseases. The strong clinical outcomes of anti-VEGF therapies, including improved visual acuity and reduced anatomical abnormalities, have also supported their widespread adoption. Additionally, growing awareness of early diagnosis and treatment, especially in urban centers, is boosting market penetration.

Market Restraints

Despite its advantages, the market faces several challenges. One major restraint is that angiogenesis is not the root cause in all tumor types, making anti-VEGF less universally effective in oncology. Additionally, safety concerns regarding intraocular injections, such as endophthalmitis and increased intraocular pressure, are hindering adoption in some regions. In developing nations, the lack of routine diabetic eye screenings results in underdiagnosis and undertreatment, curbing market growth potential.

✅Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/33243

Market Opportunities

The future of the Anti-VEGF Therapeutics Market is bright, with multiple opportunities for expansion. New formulation advancements, such as sustained-release implants and non-invasive delivery systems, promise improved patient compliance. Also, combination therapies with anti-inflammatory or anti-fibrotic agents are being explored to enhance treatment efficacy. The rise in biosimilar development, especially in cost-sensitive markets like India and Latin America, offers the potential to widen access and affordability. Moreover, increasing regulatory approvals and R&D investments in developing economies further signal strong opportunities for market expansion.

✅ Frequently Asked Questions (FAQs)

➤ How Big is the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
➤ Who are the Key Players in the Global Market for Anti-VEGF Therapeutics?
➤ What is the Projected Growth Rate of the Anti-VEGF Therapeutics Market?
➤ What is the Market Forecast for Anti-VEGF Therapeutics for 2032?
➤ Which Region is estimated to dominate the Industry through the Forecast Period?

✅ Company Insights: Key Players in the Anti-VEGF Therapeutics Market

✦ F. Hoffmann-La Roche Ltd.
✦ Biogen
✦ Pfizer Inc
✦ CoherusBioSciences
✦ Amgen Inc
✦ Regeneron Pharmaceuticals Inc.
✦ Bayer AG
✦ Novartis AG

✅ Recent Developments in the Anti-VEGF Therapeutics Market

■ In May 2020, F. Hoffmann-La Roche Ltd. announced positive Phase III clinical trial results for its ranibizumab Port Delivery System.
■ In December 2020, Roche released global Phase III results for Faricimab in treating Diabetic Macular Edema (DME), showing significant improvements.

✅ Reasons to Buy the Report

Understand the market's historical, current, and projected size from 2015 to 2032.

Gain insights into the market segmentation by product, disease type, and region.

Identify growth trends, opportunities, and challenges across geographies.

Benchmark your business against top players in the anti-VEGF space.

Evaluate recent clinical developments and pipeline products for competitive advantage.

Access comprehensive data to support strategic investment decisions.

The Anti-Vascular Endothelial Growth Factor Therapeutics Market is poised for continued yet steady growth, anchored by a globally aging population, the increasing burden of chronic diseases, and the proven efficacy of targeted therapies like Eylea and Lucentis. While growth may be modest in terms of CAGR, the market holds immense value through innovation, regional expansion, and clinical advancements. With an ever-evolving therapeutic landscape, the industry offers both stability and significant room for strategic development.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.